| Similar Articles |
|---|
 |
The Motley Fool
May 6, 2008
Brian Orelli |
Free Drugs Free over-the-counter drugs are a win-win for health insurers and their members.   |
Chemistry World
May 1, 2015
Rebecca Trager |
Generics firms in three-way takeover battle US-based Mylan is gunning for Irish rival Perrigo, but the deal is overshadowed by a bid for Mylan itself from Israel's powerhouse Teva. |
Chemistry World
July 31, 2013
Daniel Johnson |
Perrigo bags Elan and its bargain Irish tax rates US drugmaker Perrigo has agreed to buy Irish pharma company Elan in a deal worth $8.6 billion. This hands Perrigo a base in low-tax Ireland and annual savings of up to $150 million in tax and operating costs. |
Chemistry World
December 8, 2015
Phillip Broadwith |
Perrigo nabs US rights to AZ Crohn's drug Irish drug maker Perrigo has fended off a hostile takeover bid from rival Mylan, and agreed to buy the US distribution rights to AstraZeneca's gastroenterology drug Entocort (budesonide). |
The Motley Fool
October 31, 2007
Brian Lawler |
Adams On-and-Off With the FDA A new compound gets delayed, but the drugmaker still raises earnings guidance, and shares rise. Investors, take note. |
The Motley Fool
August 4, 2011
Rex Moore |
Perrigo's Growth May Not Be What It Seems Perrigo has an intangible assets ratio of 40%. |
The Motley Fool
November 13, 2006
Rick Aristotle Munarriz |
4 Stocks That Took a Hike Companies with growing yields can make you rich in more ways than the obvious. SYSCO... Perrigo... Bandag... Laidlaw... |
Chemistry World
April 13, 2015
Emma Stoye |
Generics giant Mylan offers $30 billion for Perrigo Generics manufacturer Mylan has made an unsolicited, public offer to buy Ireland-based rival Perrigo for $205 per share. |
Chemistry World
November 11, 2014
Phillip Broadwith |
Perrigo to buy Omega Pharma for euro 3.6bn The former US-based Perrigo, which reincorporated in Ireland for tax reasons after buying Elan in 2013, will make use of Omega's established distribution networks in Europe to further expand its geographic reach. |
The Motley Fool
May 21, 2009
Brian Orelli |
If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did. |
The Motley Fool
October 17, 2010
Joseph Picard |
CVS Gets Smurfed and Fined The DEA accuses CVS drugstore chain of helping fuel meth production. |
The Motley Fool
August 17, 2009
Rick Aristotle Munarriz |
7 Reasons Not to Worry This Week Let's go over seven publicly traded companies that are expected to stand tall this week: Hewlett-Packard... Perrigo... BJ's Warehouse Club... Flowers Foods... Hormel... salesforce.com... Ross Stores... |
The Motley Fool
January 2, 2008
Brian Orelli |
Congestion in the OTC Market J&J already has generic competition for its new drug Zyrtec. |
The Motley Fool
March 31, 2011
Brian Orelli |
Johnson & Johnson Hires a Babysitter J&J tries to turn the OTC business around; the McNeil Consumer Health care unit will now be headed up by Patrick Mutchler, previously the head of the health-care giant's baby products.. |
